IMP

CTCP Dược phẩm Imexpharm · HOSE

41,200 Latest close · 30 Jun 2026 P/E 20.3x P/B 2.7x

Slightly positive · CFO/NPAT 0.82x

On a TTM 2026Q1 basis, IMP shows mild improvement in both revenue and margins, but the magnitude of change is narrow — profit is at an all-time high. This signal only becomes convincing if the improvement widens in coming periods.

Revenue TTM

VND 2,393bn

+3.7%

Net Margin

14.90%

+0.5pp year on year

ROE

15.4%

TTM

View Full Financial Analysis